Calendar
April 30, 2025 - Interim Report Q1 2025 (7:00am CEST)
May 6, 2025 - Annual General Meeting
August 21, 2025 - Interim Report Q2 2025 (7:00am CEST)
November 7, 2025 - Interim Report Q3 2025 (7:00am CET)
Investors
Egetis is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious rare/niche diseases with significant unmet medical needs in the orphan drug segment
Share
Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden
Phone: +46 8 679 72 10
E-mail: [email protected]
